Form 4: Supernus Pharmaceuticals Director Georges Gemayel Reports Transaction
SEC Form 4 Filing
Director Georges Gemayel reports the acquisition and disposal of Supernus Pharmaceuticals common stock and restricted stock units on February 23, 2024.
Summary
- On February 23, 2024, Georges Gemayel, a director of Supernus Pharmaceuticals, acquired 3,886 shares of common stock.
- On the same day, Gemayel disposed of 3,886 restricted stock units.
- The restricted stock units vested on February 23, 2024, and were settled in common stock.
- Following these transactions, Gemayel beneficially owns 17,201 shares of Supernus common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the transactions of a company director.
Key Dates
| Date | Description |
|---|---|
| 02/23/2024 | Date of transaction: Acquisition of common stock and disposal of restricted stock units. |
| 02/27/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.